In medical news:

Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone. The FDA’s complete response letter identifies issues with user human factors study – which is designed to evaluate the user interface of a product – among others, Amphastar said. Amphastar already sells naloxone in pre-filled syringes, as does privately held Kaleo Pharmaceuticals, which came under fire earlier this month for raising the price of its naloxone device Evzio by 550 percent to $4,500.

Read more from Reuters Health here.

Leave a Comment

Your email address will not be published. Required fields are marked *